Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rel-Pentazocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentazocine SCHEMBL2493 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL30132413 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL2492 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16220021 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL16144643 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL18672553 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL4376337 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL680675 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| (+)-Pentazocine SCHEMBL22865258 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 | |
| Pentazocine SCHEMBL29611805 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1TMEM97OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| CN-120114438-A | Method of administering resiniferatoxin and method of treating cardiovascular disease with resiniferatoxin | 内布拉斯加大学董事会 | 2025-06-10 | — | — | CN | disclosed |
| CN-119431199-A | Preparation method and intermediate of sulfonamide compound | 上海凌凯科技股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | disclosed |
| US-20230233552-A1 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2023-07-27 | — | — | US | disclosed |
| US-11672796-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-06-13 | — | — | US | disclosed |
| US-11576908-B2 | Compositions for treating CMT and related disorders | PHARNEXT (FR) | 2023-02-14 | — | — | US | disclosed |
| CN-109310672-B | Use of sigma receptor ligands in cancer | 埃斯特韦制药有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| WO-2010115741-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING NEUROINFLAMMATORY CONDITIONS | PHARNEXT (FR) | 2010-10-14 | — | — | WO | disclosed |
| EP-2236158-A1 | New therapeutic approaches for treating neuroinflammatory conditions | Pharnext (FR) | 2010-10-06 | — | — | EP | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20090298849-A1 | Materials and Methods Relating to the Induction of Apoptosis in Target Cells | SPRUCE BARBARA ANN | 2009-12-03 | — | — | US | disclosed |
| US-7572762-B1 | Materials and methods relating to the induction of apoptosis in target cells | UNIVERSITY OF DUNDEE (GB) | 2009-08-11 | — | — | US | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| EP-1091759-A2 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIVERSITY OF DUNDEE (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000599-A2 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIVERSITY OF DUNDEE (GB) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | SIGMAR1 2013/4885OPRM1 814/4885TMEM97 4040/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | SIGMAR1 2013/4885OPRM1 814/4885TMEM97 4040/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | SIGMAR1 2013/4885OPRM1 814/4885TMEM97 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.